CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX ...

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the ...

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...

Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the ...

The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important ...

One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a ...